Current work
RESPONSE is particularly active in the field of engineering and testing of stent-based implants, as well as local drug delivery coatings for implants [1] [2] [3] . Percutaneous heart valve technology is being researched towards dedicated in vitro testing environments and artificial polymer-based leaflet materials as a replacement for current xenogenic tissue-based materials [4] [5] [6] . Numerical tools are being developed for the structural mechanical and fluid dynamical assessment of implants and implant/host interaction [7, 8] . Employing stents as a platform technology, novel applications are being addressed, such as microstents for glaucoma treatment [9] , as well as stents for the Eustachian tube for treatment of chronic otitis media. Challenges are being tackled in implant design, biofunctionalization, process development and production, see Table 1 . 
Aims and ambition
Medical device innovations pursue the central aim of contributing to the improvement of the quality of patients' lives, as well as to the extension of patient life expectancy. In this field, the consortium RESPONSE has identified key innovations in implantable medical devices and combination product technology for cardiovascular, ophthalmic and otorhino- 
The vision
The field of medical device technology as addressed by RESPONSE is of high social relevance. It holds considerable perspectives regarding the future impact on the improvement of patients' lives, see Figure 2 . In this context. the consortium will also initiate so-called smart implants and responsive implant functions for further enhancements. Successful completion of all prerequisites for clinical translation is a key objective for RESPONSE, see Figure 3 . This involves cost analysis [10] and health technology assessment. 
